# DESCRIPTION

## BACKGROUND

- motivate protein interaction networks

## SUMMARY

- summarize method of inhibiting pathogenic agents

## DETAILED DESCRIPTION

- describe cell-based multiplex approach
- illustrate inhibition of pathogenic agents
- define terms used in the invention

### Combination Compositions and Treatments

- describe combination of Bithionol with antibiotics

### Administration of the Bithionol Composition

- describe modes of administration

## EXAMPLES

### Example 1. Identification of Host Hub Proteins Exploited by Multiple Pathogenic Toxins

- identify host hub proteins

### Example 2. The Effect of Caspase Mutations on the Sensitivity of Human B-Cells to P. aeruginosa Exotoxin A

- investigate caspase mutations on PE sensitivity

### Example 3. A Multiplexed Cellular Screen for CCL Drugs that Inhibit Cytotoxic Activities of Bacterial Toxins Exploiting Unique but Interconnected Host Pathways

- screen CCL for broad-spectrum anti-pathogenic agents

### Example 4. A Multiplex Protein Function-Based Screen for CCL Drugs that Inhibit Proteolytic Activities of Host Caspase-3, -6, and -7

- screen CCL for caspase inhibitors

### Example 5. Bithionol Reduces the Pathogenicity of a Range of Toxins by Inhibiting Host Caspases

- investigate Bithionol's anti-toxin potential

### Example 6. Bithionol Inhibits Cytotoxic Activity of Anthrax Toxins

- test Bithionol's ability to neutralize anthrax toxin

### Example 7. Bithionol Inhibits Ricin and Botulinum Neurotoxin A-Induced Death In Vitro and In Vivo

- test Bithionol's ability to inhibit ricin and BoNT/A

### Example 8. Bithionol Acts as a Zika Virus Inhibitor

- investigate Bithionol's anti-ZIKV potential

### Example 9. Material and Methods

- list chemicals and reagents
- describe cell culture and cell lines
- outline cellular drug screens and caspases FRET drug tests
- detail toxins treatments and cell viability assays
- describe additional assays and animal studies

